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57) ABSTRACT 
A short route to the total synthesis of the core skeleton of the 
taxol ring system is described. The same sequence of 
transformations can be carried out to make the 7-hydroxy 
series, and connect the additional carbon atoms required for 
the A-ring. The number of steps to the taxane skeleton is 13, 
making it the shortest route from readily available inexpen 
sive starting materials. 
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SHORT SYNTHETIC ROUTE TO TAXOL 
AND TAXOL DERVATIVES 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The invention relates to the chemical synthesis of taxol, 
taxol intermediates, taxol precursors and novel taxol related 
compounds accessible through these precursors. Also 
described are pharmaceutical compositions and methods of 
use of the new compounds that have taxol-like activity. 
2. Description of Related Art 
The synthesis of the diterpene alkaloid taxol has been a 
popular target for total synthesis for the past ten years; 
however, it is only recently that the need for a total synthesis 
has taken on a new urgency in view of its medical impor 
tance in breast cancer treatment (Time, 1991) and more 
recently a possible treatment in kidney disease (Pharmaceu 
ticals & Biotech Daily, 1994). Taxol is in phase II/phase Ill 
clinical trials and is showing extremely promising activity, 
particularly against ovarian, breast and lung cancers (Row 
insky, et al., 1990). Taxol has several advantages over other 
antitumor agents currently in use, including its relative lack 
of toxicity compared to other antitumor agents such as 
vinblastine and vincristine. Consequently, taxol has become 
the focus of a large number of antitumor programs both in 
academia and in the pharmaceutical industry (Klingston, et 
al., 1990; Winkleer, 1992; Swindell, 1991). Unfortunately, 
this effort, intended to explore the full range of tumor 
response to taxol chemtherapy, is severely limited by the 
scarcity of taxol itself. 
Taxol is isolated from the North American Yew tree but 
only in very small amounts, requiring a time-consuming 
purification. The yew tree is an environmentally protected 
species and cannot be considered a permanent source of 
taxol. Even if this were not the case, the total yew tree 
population is estimated to yield only enough taxol for 
approximately one year of clinical evaluation. 
Even if Taxol supplies were abundant, it has become 
apparent that potency of the drug is relatively low so that 
there is a particular need to obtain quantities sufficient to 
develop more active derivatives and analogs of this prom 
ising drug. French researchers have recently claimed that 
certain derivatives of taxol such as taxotere are more potent 
than the parent (Mangatal, et al., 1989; Colin, et al., 1988). 
Therapeutic protocols presently require dose levels of 500 
mg per patient, making it even more imperative to develop 
alternate sources of the drug or to devise an efficient 
chemical synthesis. Current supplies are inadequate to afford 
treatment to all patients for whom this drug is indicated. 
There is therefore a need to provide a chemical synthesis 
of taxol efficient enough to supply large quantities (>100 
kilos), and flexible enough to provide analogs in order to 
explore structure activity relationships (SAR). Such struc 
ture activity relationships for taxol and taxotere are the 
subject of current research (see, for example, Ojima, et al., 
1994). Analogs and derivatives of taxol offer potential for 
more effective treatment of breast cancer with the goal of 
developing more selectivity and higher potency. Addition 
ally, as with most cancer therapy, resistance to treatment is 
usually encountered, creating a need for second and third 
generation derivatives of the active parent compound. 
Currently, research groups attempting to develop a total or 
partial synthesis of taxol, while making some progress, have 














steps (Borman, 1991). This is far too long to be of any real 
practical commercial use, as anything more than 25 steps is 
not considered to be practical (Science, 1994). The synthesis 
of taxol should be no more than about twenty steps, and it 
is essential that the synthesis be enantiospecific. 
The synthesis of taxol is, however, complicated by its 
different functional groups, making it difficult to predict the 
effect of modifications in one part of the molecule on other 
positions. Recently, total synthesis of taxol has been 
reported (Holton, et al., 1994; Nicolaou, et al., 1994). While 
of scientific significance, these syntheses do not appear to be 
commercially viable routes to taxol because the number of 
synthetic steps is quite high and because overall yields are 
low (Science, 1994). 
It is therefore desirable to develop a simple, efficient 
synthetic route to taxol. Intermediates along the route as well 
as the end product will provide compounds so as to be able 
to determine the effect of structure activity relationships. 
This will lead to improvements on the natural form of taxol 
and will provide a rational approach in reducing toxicity and 
increasing efficacy. 
SUMMARY OF THE INVENTION 
The present invention seeks to overcome these and other 
drawbacks inherent in the prior art by providing a relatively 
short, efficient synthesis of the core structure of taxol. The 
disclosed syntheses address all the issues of the large num 
ber of functional groups from the outset, and are not simply 
models on which to conduct research studies. Furthermore, 
the strategy is amenable to large scale operation, employing 
reactions and readily available reagents that can be used by 
process manufacture groups experienced in the pharmaceu 
tical industry. 
Most importantly, the synthesis involves relatively few 
steps considering the complexity of the molecule. As a 
general rule, the synthesis of a diterpene (20 carbon atoms 
in the core structure) is acceptable with twenty steps. The 
added complexity of the multiple oxygen functionality 
would be expected to add at least another ten steps, making 
a total of thirty steps. The present invention, utilizing readily 
available and inexpensive starting materials, provides a total 
synthesis of taxol in significantly fewer steps. As disclosed 
herein, total synthesis of the A/B/C taxol system is accom 
plished in 13 steps (see scheme 21). This contrasts with 
recently published total syntheses of taxol by two different 
groups; Holton, et al. (1994) and Nicolau, et al. (1994) that 
appear to require 45-50 steps if one assumes starting with 
simple, commercially available materials. 
The present invention provides a commercially practible 
total synthesis of the A, B and C rings of taxol and allows 
for a wide variety of structural variations at positions 7, 8, 
12, 16, and 17. Two major synthetic routes are described. 
The first involves ring expansion of seven-membered ring 
intermediate into an eight membered ring to provide ring B 
of taxol. In a second approach, B ring synthesis involves 
cyclopropanation of a seven-membered O.B-unsaturated 
ketone followed by reductive or nucleophilic opening of the 
internal cyclopropane bond to give the eight-membered B 
ring. The second strategy provides the eight-membered ring 
more directly. The taxane numbering system and the corre 
sponding numbering system for taxol are shown in FIGS. 1A 
and 1B. 
There are several advantages to the synthetic procedures 
described herein. A major advantage is that synthesis of the 
taxol A, B, C ring system does not require complex or 
5,508.447 
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expensive starting materials. The entire synthesis is possible 
from simple, inexpensive, and commercially available pre 
cursors. The starting materials referred to in scheme 2, i.e., 
the three-bromoester of propanoic acid and methacrylol 
chloride (or substituted analogs, e.g., the substitution of the 5 
methacrylol methyl group by alkyl or aryl groups) may be 
employed by selecting, for example, any of a relatively wide 
choice of O.B-unsaturated acid chlorides. The methyl or 
other R group provided by the acid chloride will ultimately 
provide the 19-substituent in the taxol system. Different 
protecting groups can be used other than t-butyldimethylsi 
lyl. Such protecting groups are considered in the usual range 
of standard alcohol protecting groups and should be selected 
with the proviso that they are stable to subsequent aldol or 
Claisen reaction, lithium aluminum hydride reduction, and 
oxidative rearrangement. This would therefore exclude 
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MeS-N-N- CO2Et -T Ge. H O CHO 
5 & 
7 (R = SiMe2But, R = H) 
8 (R = SiMe2But, R1 = Me) 
Compound 9 (Scheme 5) is synthesized through conden 
sation of compound 5 with any of a number of substituted 
furans. Where R is methyl, the C-16/17 methyl of taxol is 
derived from the C-3 methyl group of the furan. Depending 
on the conditions, the substituent at the 2-position of the 
furan may either be an aldehyde or an ester. When an 
aldehyde furan is used reactions are typically run at -78 
C.(CO-acetone). Where 2-substituted esters are used the 





drofuran at 25°C. If ring expansion takes place in the top 
half of the 7 membered ring precursors then the C-4 methyl 
group also becomes the C-16/17 methyl group. The methyl 
group may be replaced by alkyl, aryl, etc. Additionally, the 
aldol reaction may be performed in the presence of different 
amide bases where esters instead of furan aldehydes are 





Me COEt-TT Ge. 
H O COMe 
5 & 
Me 
9 (R = SiMe2Bu) 
The reduction of compound 7 tp gove 10 (Scheme 6) is 
shown using lithium aluminum hydride in tetrahydrofuran 
but similar results are also obtained using lithium borohy 
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8 (R = SiMe2But, R = Me) 
10 (R = SiMe2Bul, R = H) 








Selective protection of the hydroxyl group of compound so 
10 with the trityl group is shown in Scheme 7. The hydroxyl 
group may also be protected with tert-butyldimethylsilyl or 
any other commonly used alcohol protecting group. The 
protected furan compound 12 is conveniently oxidized to the 
6 
pyranenone using singlet oxygen. Typically one would 
employ oxygen and a sensitizer such as Rose Bengal in the 
presence of light such as provided with a tungsten lamp 
(Scheme 8). t-Butylhydroperoxide/VO(acac) can also be 
used to convert 12 into 14. 
Scheme 7 (Tr = CPha) 
OH TrC/base G 
10 (R = SiMe2But, R = H) 
11 (R = SiMe2But, R1 = Me) 
OTr 
12 (R = SiMe2But, R = H) 
13 (R = SiMe2Bul, R = Me) 
Scheme 8 (Tr = CPha) 
OTr singlet oxygen or G 
t-BuOOHIVO(acac), 
12 (R = SiMe2But, R1 = H) 
13 (R = SiMe2But, Ric Me) 
14 (R = SiMe2But, R = H) 
15 (R = SiMe2But, R1 = Me) 
The conversion of 14/15 to the cycloheptenones 18, 19.20, 
and 21 is readily accomplished by acetylation (Scheme 9). 
In preferred practice, acetic anhydride is used but other 
anhydrides may be used. The formation of the ylide and 
subsequent cyclization can be in toluene at temperatures 
ranging from 25°-110° C. Other solvents can be used such 
as dichloromethane, acetonitrile, dimethylformamide, tet 
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OTBS 
Me 
18 (R1 = H) 
19 (R1 = Me) 
45 
OTBS 
20 (R = H) 
21 (R1 = Me) 
8 
As is apparent, this synthetic scheme is readily adapted to 
the synthesis of a variety of cycloheptenones having the 
general structure shown in FIG. 2. Thus, the R, R, and R" 
groups can be methyl or virtually any alkyl or aryl group. PG 
represents a protecting group. While benzyl as protecting 
group is preferred, methoxy methyl (MOM) may also be 
used as well as substituted benzyl ethers such as 4-meth 
oxybenzyl. Such syntheses are based on the use of a 
hydroxymethyl substituted furan. 
The hydroxymethyl derivatives are obtained from furan 
esters such as compound 24 by reduction of the esters to the 
corresponding alcohol with a reducing agent such as lithium 
aluminum hydride, conversion into the dilithio derivative, 
e.g., with n-Buli followed by a treatment with CO to give 
an acid group at position 5 and conversion of the original 
ester into an alcohol group. The resulting hydroxyacid may 
be converted into the di-O-benzyl derivative and subse 
quently hydrolysed to the acid which may be converted into 
the acid chloride. This synthetic scheme allows variations at 
the OR group, e.g., OMOM. This is illustrated in Scheme 10. 
Me(R) Me(R) 
( -> A V -> 
O COMe O 
24 25 
Me(R) 
Li / O \ OLi 
25a 
Me(R) 
R / \ OR 
O 
O 
26 (R = H, R = OH) 
27 (R = Bn, R'=OBn) 
28 (R = Bn, R = OH) 
29 (R = Bn, R = Cl) 
Scheme 11 illustrates the inventors' synthetic scheme to 
provide the B and C rings of taxol in the appropriate and 
correct absolute configuration. This same sequence of reac 
tions has also been used to make the 7-desoxy analogue. 
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38 
H O SoTr(TBS) 
Different chiral auxiliaries may be used. In addition to the 
norephedrine illustrated, for example, phenylglycinol and 
other similar compounds as are known to those of skill in the 
art. In the example shown and as would be the case with 
other chiral auxiliaries, the chiral auxiliary can be recovered 
and recycled. The ester 5 is converted into the chiral amide 
30 and subjected to a Claisen condensation reaction with the 






reduced in situ with lithium borohydride to give 32. The 
primary alcohol group in 32 is selectively protected as either 
a trityl or tertbutyldimethylsilyl ether to give 33. Oxidative 
rearrangement of 33 using the procedure shown or singlet 
oxygen provides the pyramenone 34. Acetylation and heating 
in toluene in the presence of DBU provides compound 35. 
A similar sequence of transformations may be carried out in 
the 7-desoxy series to give compound 38 (Scheme 12). 
Ring expansion in the 7-deoxy series is shown in Schemes 
13 and 14. Conjugate addition of MeMgBr catalyzed by Cu" 
gave 39. Use of ethyl, propyl, etc. Grignard reagents gives 
rise to different C-17 groups and may be used to provide 
other alkyl, vinyl, allyl, or aryl groups at this position. 
Removal of the alcohol protecting groups gave compound 
40. Reductive cleavage of the C-O bond and intramolecular 
ketalization lead to compound 41. The primary alcohol may 
be activated by formation of the triflate derivative 42. 
Primary alcohol activation is not limited to use of the triflate 
group and other activating groups such as mesylate, tosylate 
and the like may be employed. 
Scheme 3 





(Ring expansion in the 7-deoxy series at a higher oxidation level) 
14 
Solvolysis of compound 42 in a polar solvent such as of the oxido bridge. Treatment of compound 39 with potas 
methanol results in ring expansion of the 7 membered Bring sium bis(trimethylsilyl)amid/paraformaldehyde gives the 
to the 8 membered ring 43. While methanol is a preferred 47. Coni 
solvent, other alcohols may be used, including ethanol, enone 47. Conjugate addition of nitropropane to give 48 was 
propanol, butanol, isopropyl alcohol, and the like. The accomplished using potassium carbonate in dimethylsulfox 
ketone 43 readily forms the ketal 44 on exposure to mildly ide. While nitropropane was used to illustrate this synthesis, 
acidic conditions. 20 
other nitroalkanes may be employed, thereby allowing ver 
In the 7-desoxy series, the alcohol 41 has been oxidized ility in having diff 
to the aldehyde 45 (Scheme 14). Upon treatment with boron satility in having different substituents at the 12 position. 
trifluoride etherate, BFOEt, 45 undergoes rearrangement Removal of the TBS protecting group in conversion of the 
to compound 46. Compound 46 has the correct trans fusion as nitro group into a carbonyl group (Nef reaction) gave 49. 
between the B and C rings. 
The synthesis shown in Scheme 5 outlines a route that 
attaches the remaining A ring carbon atoms and allows for 
ring expansion without the necessity for reductive cleavage 
Schene 15 











Oxidation of compound 49 provides the aldehyde 50. 
Hydrogenolysis of the benzyl ether followed by trific anhy 
dride gave the triflate 51. Treatment of 51 with methanol/ 
2,6-di-tert-butyl-4-methylpyridine at 60° C. resulted in ring 
expansion to give the adduct of 52 which rapidly formed the 
furan 53 and eventually gave compound 54. The structure of 
compound 54 was confirmed by X-ray. 
The furan ring can be formed prior to ring expansion, see 
Scheme 16. Treatment of 50 with p-toluenesulfonic acid in 
benzene gave the adduct 55. Hydrogenolysis, triflate forma 
tion and solvolysis in methanol gave 53, which was rapidly 
convert into 54. Solvolysis in other alcohol solvents such as 
















Scheme 17 further illustrates synthesis with different 
group substituents at C-12. As discussed, this is readily 






The shortest approach to the B/C and A/B/C ring system 
is by cyclopropane internal C-C bond cleavage. Scheme 18 
shows that an activated enone such as 59 (CN can be 
replaced by -COMe, COR) can be cyclopropanated to 
give the adduct 60. Treatment of 20 with bromine followed 







enone 59 is readily converted to 60 in 95% yield when 
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When 60 is exposed to reductive cleavage conditions 
(e.g., sodium naphthalenide/THF) the internal cyclopropane 
C-C bond is cleaved to give 61 in 95% yield. The structure 
and stereochemistry of 61 was obtained by X-ray crystal 
lography. The nitrile 61 reacts with vinyl lithium to give, 
after acidic workup, the taxol precurser 63. Treatment of 62 
with lithium diisopropylamide followed by Eschenmosers 
salt (CH=NMe"I) and treatment of the resulting adduct 
with methyl iodide/acetonitrile, followed by titanium tetra 
chloride resulted in 63. This is a preferred route to the core 
taxane skeleton as it is an requires surprisingly few steps 
with high overall yields. 
Overall, the synthetic procedures discussed allow key 
structural variations at the 7, 8, 12, 16, and 17 positions 
(FIG. 3) of the A,B and C rings of taxol. The synthesis 
provides an efficient and commercially viable route to the 
total synthesis of taxol and taxol-like compounds and, more 
importantly, a synthetic route to novel taxols and interme 








The invention not only provides an efficient synthetic 
route to taxol and related compounds, but also gives access 
to taxol derivatives that may offer therapeutic advantages 
such as decreased toxicity. The inventors therefore contem 
plate that many of these compounds will be useful not only 
as important intermediates in the total synthesis of taxol but 
also as therapeutic agents themselves. Such compounds are 
readily formulated for use as pharmaceutical agents and may 
for example be prepared for oral or parenteral administra 
t1O. 
For parenteral administration in an aqueous solution, for 
example, the solution should be suitably buffered if neces 
sary and the liquid diluent first rendered isotonic with 
sufficient saline or glucose. These particular aqueous solu 
tions are especially suitable for intravenous, intramuscular, 
subcutaneous and intraperitoneal administration. In this con 
nection, sterile aqueous media which can be employed will 
be known to those of skill in the art in light of the present 
disclosure. For example, one dosage could be dissolved in 1 




hypodermoclysis fluid or injected at the proposed site of 
infusion, (see, for example, "Remington's Pharmaceutical 
Sciences' 15th Edition, pages 1035-1038 and 1570-1580). 
Some variations in dosage will necessarily occur depending 
on the condition of the subject being treated. The person 
responsible for administration will in any event determine 
the appropriate dose for the individual subject. 
Upon formulation, solutions will be administered in a 
manner compatible with the dosage formulation and in such 
amount as is therapeutically effective. The formulations are 
easily administered in a variety of dosage forms such as 
injectable solutions, as mentioned, or as drug release cap 
Sules, oral preparations and the like. 
All such formulations, whether for oral or injectable 
administration, will of course be prepared so as to be 
"pharmaceutically acceptable", that is, with molecular enti 
ties and compositions that do not produce an allergic or 
similar untoward reaction when administered to a human. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1A shows the structure and numbering for the taxane 
ring system. FIG. 1B shows the structure of taxol where Ac 
represents an acetate group and BZ a benzoyl group. 
FIG. 2 shows several cycloheptenone compounds acces 
sible from the disclosed synthesis, useful as key intermedi 
ates in the synthesis of taxol and taxol derivatives. The R, R' 
and R" groups are independently lower alkyl, aryl or hydro 
gen. Protecting groups (PG) are typically benzyl, methoxy 
methyl (MOM) or 4-methoxybenzyl. 
FIG.3 shows the positions in the A,B and Crings of taxol 
where different groups can be substituted. 
FIG. 4 shows the degradation of taxol. 
DETALED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
There are two important structure activity relation (SAR) 
features of taxol that should be taken into consideration in 
the synthetic design. The amino-alcohol side chain at C-13 
is essential for antitumor activity (Ojima, et al., 1992; 
Farina, al., 1992; Georg, et al., 1992). Methods are known 
for the conversion of the C-13 alcohol into taxol (Denis, et 
al., 1988; Holton, 1991; Holton, 1992; Holton, 1993). 
The oxetane, C-20, C-4 and C-5, also appears to be 
essential for full biological activity (Samaranayake, et al., 
1991; Denis, et al., 1988). Simple model studies demonstrate 
that the oxetane functionality is readily constructed (Magee, 
et al., 1992; Berkowitz, et al., 1987; Lin, et al., 1987; 
Nicolaou, et al., 1992) and recent work has also described 
more complicated compounds with the oxetane intact (King 
ston, et al., 1990). 
In the following examples, two series of compounds are 
described; one with all the oxygen functionality and the 
other as the 7-desoxy series. 
EXAMPLE 1. 
This example shows the strategy for the synthesis of a 
hydroxypyranenone which provided the basis for the ste 
reoselective synthesis of the taxol core structure. The reac 
tions are shown in Schemes 1 through 9 with numbers in the 















The starting material was ethyl 6-methyl-5-oxo-6-hep 
tanoate 3, comprising carbon atoms C-9, 8, 19, 7, 6, 5, 4 and 
20 of the taxol core. The ester 3 is a known compound and 
is readily prepared on a large scale (354 g., 92%) by the bis 
(triphenylphosphine)palladium(II) chloride catalyzed cou 
pling of methacryloyl chloride in toluene with the orga 
nozinc reagent 2 (Smith, et al., 1973; Tamaru, et al., 1988). 
Ethyl 4-bromobutyrate may be converted directly into ethyl 
6-methyl-5-oxo-6-heptanoate 3 (Jubert and Knochel, 1992), 
by conducting the above reaction in the presence of n-BuN" 
I. 
The C-5 carbonyl group is selectively reduced with 
sodium borohydride/cerium (III) chloride heptahydrate in 
ethanol to give (E)-ethyl 5-hydroxy-6-methyl-6-heptenoate 
4 (265 g., 80%)(Luche, 1978). Both enantiomers of 4 are 
readily synthesized. Reduction of the C-5 carbonyl group 
with borane-dimethylsulfide in tetrahydrofuran in the pres 
ence of a catalytic amount of the chiral reagent (S)-(-)- 
diphenyl-2-pyrrolidino methanol oxaazaborole gave the 5R 
enantiomer of 4 (89%)(Corey, et al., 1987; Corey and 
Bakshi, 1990; Mathre, et al., 1991; Jones, et al., 1991). The 
enantiomeric excess is >93% as judged from the H NMR 
spectrum of the derived Mosher ester. The (R)-(-)-diphenyl 
2-pyrrolidino methanol oxaazaborole catalyst gave the 5S 
enantiomer of 4, which corresponds to the natural absolute 
configuration of taxol at the C-7 secondary hydroxyl group. 
This route is not dependent upon a naturally occurring chiral 
starting material, thereby giving access to both enantiomers 
of the precursors. The chirality is introduced by reagents that 
are used in catalytic quantities. 
The secondary hydroxyl group in 4 was protected as the 
t-butyl dimethylsilyl ether (TBS) by treatment with 
TBSOTf/NEtPr', to give 5 (98%); for example, other pro 
tecting groups are also suitable, e.g., methoxymethyl 
(MOM) ethers. 
Treatment of 5 with lithium diisopropylamide in tetrahy 
drofuran at -78° C. followed by either 2-furfural or 3-me 
thyl-2-furfural gave the aldol products 7 (98%) and 8 
(100%) respectively. The aldol reaction gives two sets of 
diastereomers which can be separated. In the optically active 
series the stereochemistry at the furan carbinol is not impor 
tant, but the newly created asymmetric carbon atom adjacent 
to the ethyl ester (C-4, taxol numering) controls the absolute 
stereochemistry at the quaternary methyl (C-8, taxol num 
bering). To control the absolute stereochemistry at C-4 (and 
eventually at C-8) the (1S,2R)-(+)-norephedrine was used 
as a recyclable chiral auxiliary (Gage and Evans, 1989; 
Evans, et al., 1981; Evans, et al., 1981). 
The same type of condensation at a higher oxidation level 
(Claisen-condensation) was conducted. Treatment of 5 and 
ethyl 3-methyl-2-furoate with lithium bis(trimethylsilyl) 
amide in treathydrofuran at 25° C. gave the B-keto ester 9 
(>95%) as a mixture of diastereomers. Both diastereoiso 
mers of 7, 8 and 9 were taken through the subsequent 
reactions for two purposes; first, to assess the stereochemical 
requirements of the intramolecular pyrylium-ylide cycliza 
tion in a relative and absolute stereochemical sense; sec 
ondly, to have access to unnatural seteroisomers of the taxol 
precursors for biological evaluation. 
Only the natural absolute taxol stereochemistry is shown 
in FIG. 2, but it should be understood that all the diastere 
omers and their mirror images are readily separated to allow 
use in pure form rather than mixtures. The separation of the 
pure diastereomers in the optically active series is best 
carried out after the key pyrylium-ylide cyclization. The use 
of the chiral auxiliary approach in the 7-oxy series as 
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described in Example 3 makes separation unnecessary, and 
a single optically active natural absolute stereochemistry 
versions of 20 and 21 becomes available. 
Reduction of 7 using lithium aluminum hydride in tet 
rahydrofuran added at -78° C. and warmed to 25° C. gave 
10 (99%). Similarly, reduction of 8 gave the methyl analog 
11 (100%). The primary hydroxyl group in 10 and 11 was 
protected as the triphenyl methyl ether (trityl ether). Treat 
ment of 10 with triphenylmethyl chloride in dichlo 
romethane followed by triethylamine and 4-dimethylami 
nopyridine (DMAP, 0.1 equiv) gave the trityl ether 12 
(97%). Similarly, the methyl analog 11 gave the correspond 
ing trityl ether 13 (>90%). Other protecting groups for the 
primary alcohol can be used; for example, the primary 
t-butyldimethylsilyl ethers. 
Oxidation of the furan carbinol 12 in dichloromethane 
with tert-butyl hydroperoxide in the presence of a catalytic 
amount of vanadyl acetyl-acetonate (Ho and Sapp, 1983) at 
-10°C. gave the rearranged hydroxypyranenone 14 (98%). 
The methyl analog 13 gave 15 in 98% yield. 
The hydroxypyranenone 14 was converted into its derived 
acetate 16 by treatment with acetic anhydride in dichlo 
romethane containing pyridine or triethylamine and a cata 
lytic amount of 4-dimethylamino pyridine (DMAP). It is not 
necessary to purify the acetate since it can be used directly 
in the pyrylium ylide cyclization reaction. 
EXAMPLE 2 
The key reactions for the synthesis of the core taxol 
structure are shown in Scheme 9. Results of this work 
indicated that the C-4 substituent stereochemistry controls 
the stereochemistry of the angular methyl group at C-8. The 
numbering system for taxol is shown in FIG. 1. 
Pyrylium Ylide Cyclization. 
The acetate 16 is a single stereoisomer at C-7 and a 
mixture at C-4. The other two stereogenic centers are 
destroyed in the conversion of 16 into the pyrylium ylide 
intermediate A/B. Therefore, in principle, heating 16 should 
give rise to the two pyrylium ylides A and B which can 
undergo intramolecular cycloaddition to give four products 
18, 20, 22 and 23. In the racemic series the same compounds 
would be formed along with their mirror-image antipodes. 
The same situation prevails for the methyl analog series. 
Unexpectedly, heating 16 in dichloromethane or more rap 
idly in toluene in the presence of DBU gave only two 
cycloaddition productions 18 and 20 (65-85%) (Katritzky 
and Dennis, 1989). This result indicated that the C-4 sub 
stituent stereochemistry controls the stereochemistry of the 
angular methyl group C-8. The C-8 methyl group is always 
trans to the C-4 substituent. The methyl group at C-8 is also 
always trans to the oxygen bridge in the newly formed 
tetrahydrofuran ring in order to maintain the thermodynami 
cally preferred cis fusion of this ring to the cyclohexane ring. 
This result was significant because it showed that of all the 
possible stereoisomers of 16, only one, namely the 4R, 7S 
diastereoisomer, gives the correct absolute stereochemistry 
at both C-7 and C-8. 
In the racemic series the relative stereochemistry of 18 
was established by single crystal X-ray crystallography. In 
the optically active series the absolute stereochemistry of the 
mirror image of 18 was established by single crystal X-ray 
crystallography of a derived camphanic acid ester. 
Similarly in the methyl series heating 17 in the presence 
of DBU in dichloromethane or toluene gave 19 and 21 














fractional crystallization or by chromatography of the detri 
tylated derivatives. The tricyclic enone 21 contains carbon 
atoms C-2, 3, 4, 20, 5, 6, 7, 8, 19, 9, 10, 11, 15 and 16 (or 
17) of the taxol core. The C-ring is intact, and the B-ring 
requires a one carbon ring expansion from a seven-mem 
bered ring to an eight-membered ring to complete the carbon 
skeleton. 
Based on these results, a series of transformations was 
performed using a more elaborate furan that incorporates an 
extra carbon atom destined to become part of the eight 
membered ring. These reactions are shown in Schemes 
10-17. The known furan 24 was reduced with lithium 
aluminum hydride to give the derived alcohol 25. The 
alcohol 25 was treated with n-butyl lithium followed by 
carbon dioxide to give the acid 26. Treatment of 26 with 
benzyl bromide/sodium hydride/dimethylformamide gave 
27 which was directly hydrolyzed to the acid 28 using 
sodium hydroxide in isopropanol. The acid 28 was con 
verted into the acid chloride 29 by treatment with oxalyl 
chloride (sodium salt). 
The acid chloride 29 was treated with the lithium enolate 
derived from the amide 30 to give the adduct 31 which was 
reduced with lithium borohydride to give the diol 32 and the 
recoverable chiral auxiliary. The diol 32 was protected as the 
t-butyl dimethylsilyl ether 33 or trityl ether. (Scheme 11). 
The ether 33 was oxidized using tert-butyl hydroperoxide in 
the presence of a catalytic amount of vanadyl acetylaceto 
nate (Ho and Sapp, 1983) at -10° C. to give the rearranged 
hydroxypyramenone 34. The hydroxypyramenone 34 was 
converted into its derived acetate by treatment with acetic 
anhydride in dichloromethane containing pyridine or tri 
ethylamine and a catalytic amount of 4-dimethylamino 
pyridine (DMAP). It was not necessary to purify the acetate 
since it could be used directly in the next stage. Heating the 
acetate in dichloromethane or more rapidly in toluene in the 
presence of DBU gave only two cycloaddition products 35 
(79% from 31) and the diastereomer corresponding to 18/19. 
Only the diastereomer with the correct absolute configura 
tion, namely 35 is shown. In the series with a chiral 
auxiliary, described in Example 3, the compound 35 was 
obtained as a single diastereomer and did not require any 
separation from unnatural stereoisomers. 
EXAMPLE 3 
A unique approach to synthesis of the taxol core structure 
is illustrated in this example. The results demonstrate that 
transannular interactions across the eight membered B ring 
of taxol are an intrinsic property of these structures. 
Taxol is not a particularly potent antitumor drug, and it is 
suspected that it is extensively degraded before it reaches the 
target cells. A plausible pathway for its degradation is shown 
in FIG. 4. It involves the known reversible retro-aldol 
process that causes C-7 epimerization to give 65 via the 
aldehyde 64, and irreversible B-elimination of the C-5 
oxetane C-O bond to the ol,B-unsaturated aldehyde 66. Since 
it is known that the oxetane is necessary for activity this 
degradation would greatly reduce the potency of taxol. A 
way to prevent this process is to remove the C-7 hydroxyl 
group. Previous efforts to carry out this deoxygenation on 
taxol have failed. The only identifiable materials were ring 
B cleavage products. Consequently, 7-desoxytaxol 67 is a 
very important target for total synthesis. 
Using the same strategy employed for the synthesis of 
20/21 the methallyl chloride was converted into ethyl 6-me 
thylhept-6-enoate 68 (70%). Conversion of 68 into 72 via 
69, 70 and 71 utilizes the same chemistry as in the 7-hydroxy 
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series. The reaction scheme is shown in Scheme 19. The 
same sequences of transformations can be carried out with 
the C-4 carbinol protected as a t-butyldimethylsilyl ether or 















Using the more elaborate furan 27a, the ester 68 was 
treated with lithium diisopropylamide and quenched with 
27a to give 73. Scheme 20 illustrates the reaction scheme. 
Reduction of 73 using lithium aluminum hydride followed 
by protection of the primary hydroxyl group with t-bu 
tyldimethylsilyl chloride gave 74 (80% from 68). Oxidation 
2. DBU/toluene A G 
50 
26 
of the furan carbinol 74 in dichloromethane with tert-butyl 
hydroperoxide in the presence of a catalytic amount of 
vanadyl acetyl-acetonate at -10° C. gave the rearranged 
hydroxypyranenone 75 (90%). Treatment of 75 with acetic 
anhydride followed by heating the derived acetate intoluene 
(R)Me 

















in the presence of DBU gave 38 (64%). The additional 
methyl of the gem methyl group was introduced by treat 
ment of 38 with methyl magnesium bromide in the presence 
of a catalytic amount of CuBr.SMe in tetrahydrofuran to 
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38 (see Scheme 12) 
Hydrogenolysis and mild acid hydrolysis of 39 removed 
both the benzyl and t-butyldimethylsilyl ether protecting 
groups resulting in the diol 40. Treatment of 40 with 
Zn/HgCl2/HO+ resulted in reductive cleavage of the oxido 
bridge and intramolecularketalization to give 41 (80%). The 
carbinol 41 was converted into the trifluoromethane 
sulfonate derivative 42 by standard methods. Solvolysis of 
42 in methanol resulted in ketal fragmentation, followed by 
ring expansion and proton loss, to give the eight-membered 
ring ketone 43. Exposure of 43 to aqueous acid gave the 
hemiketal hydrate 44, whose structure was confirmed by 
X-ray. Heating 44 converted it back into the ketone 43. 
These results revealed the advantage of differentiation of the 
two ketone carbonyl groups in 43 (Scheme 13). 
The rearrangement may be carried out at a higher oxida 
tion level to give a more functionalized eight-membered 
ring. Oxidation of the carbinol 44 using TPAP (cat)/NMNO 
(Griffith and Ley, 1990) gave the aldehyde 45, which upon 
treatment with BFOEt resulted in rearrangement to give 
46. The compound 46 has the C-10 ketone thereby enabling 
functionalization at C-9, and the correct trans B/C ring 






39 (see Scheme 13) 
Control of Absolute Stereochemistry 
To control the absolute stereochemistry at C-4 (and even 
tually at C-8), (1S,2R)-(+)-norephedrine and R-(+)-pheny 
lalanine were employed as recyclable chiral auxiliaries. 
Compound 30 (ee>90%) was synthesized using chiral 
Claisen technology (Evans, 1981). The amide in 31 was 
readily reduced using lithium borohydride in tetrahydrofu 
ran to give the diol 32 and the recoverable chiral auxiliary. 
The reactions are shown in Scheme 11. 
An identical sequence of transformations in the series 
with the C-7 hydroxyl substituent absent was carried out. 
(Scheme 18). Consequently, all of the compounds described 
in both antipodal forms (i.e. both natural and unnatural 
absolute stereochemistry) are accessible. 
EXAMPLE 4 
Scheme 21 outlines a total synthesis of the A/B/C ring 
system of taxol with the correct stereochemistry. The 
approach is based partly on the "cyclopropane” approach to 
ring expansion to the B/C rings. The entire sequence is 13 





Scheme 21 (Flow Chart for the Cyclopropane Approach, X = OTBS or H) 
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The overall route in scheme 21 comprises thirteen steps 
from the readily available heptenoate ester. Hydrolysis to an 
acid and activation of the acid by conversion into an acid 
chloride, followed by addition of the lithium salt of the 
chiral auxiliary resulted in the precursor in three steps. 
Claisen condensation and reduction in the same reaction 
vessel produced the diol which is protected on the primary 
alcohol and oxidatively rearranged to provide the pyrylium 
ylide precursor in three steps. Acetylation of the pyrylium 
ylide precursor, and heating in the presence of DBU, gave 
the cycloheptenone in two steps. Bromination of the cyclo 







activated cyano-enone in two steps. Gem-methyl cyclopro 
panation and reductive cleavage of the internal cyclopropane 
bond resulted in ring expansion to form the eight-membered 
ring B of the taxol core skeleton in two steps. Finally, 
treatment of the eight membered-ring cyano compound with 
vinyl lithium followed by acidic workup formed the A-ring 
of taxol in one step. 
The inventor has discovered that the fourth step in the 
synthesis providing the precursor diol is readily performed 
as a "one-pot' reaction. The Claisen condensation shown 






a reducing agent such as lithium borohydride to give the 
diol. 
While the compositions and methods of this invention 
have been described in terms of preferred embodiments, it 
will be apparent to those of skill in the art that variations may 
be applied to the compositions, methods and in the steps or 
in the sequence of steps of the method described herein 
without departing from the concept, spirit and scope of the 
invention. More specifically, it will be apparent that the 
synthesis allows for a route to a wide variety of novel taxol 
related compounds and that modifications of the overall 
synthesis by well known procedures and reactions may be 
employed. All such similar substitutes and modifications 
apparent to those skilled in the art are deemed to be within 
the spirit, scope and concept of the invention as defined by 
the appended claims. All claimed matter and methods can be 
made and executed without undue experimentation. 
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What is claimed is: 
1. A method of synthesis of the A/B/Cring system of taxoi o 
having the structure I where X is H or OH and R, R and R. 
are independently H or lower alkyl, comprising the steps; 
15 
20 
(a) reacting compound II by gem-alkyl cyclopropanation 
of the activated enone where EWG is a cyano, ester or 25 
aldehyde group, PG is an O-protecting group and R is 






(b) to form the adduct III where R and R are indepen 
dently H or lower alkyl; 
III 
(c) cleaving the internal cyclopropane C-C bond of III 
under reducing conditions to form IV; 
IV 
o N OPG 
(e) treating V under acidic conditions to ring close and 
removing the O-protecting group to form I. 
  
